---
title: "Cytisinicline: Smoking cessation"
description: "Formulary evidence on Cytisinicline in Smoking cessation. Clinical evidence covers ORCA-2, ORCA-3, ORCA-OL, ORCA-1, ORCA-V1, ISRCTN37568749, and 20 further headings. 335 evidence topics quoted from 83 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/cytisinicline--smoking-cessation"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Cytisinicline: Smoking cessation

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Cytisinicline

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Smoking cessation

<a id="topic-1.1.1-1"></a>

##### Summary

In 2022, 11.6% of U.S. adults, approximately 28.8 million people, reported current cigarette smoking. CDC attributes more than 480,000 U.S. deaths annually to smoking and secondhand smoke and reports that more than 16 million Americans live with a smoking-related disease. Estimated U.S. smoking-related costs exceeded $600 billion in 2018.

Source: [VanFrank et al. (2024)](https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm); [CDC Cigarette Smoking](https://www.cdc.gov/tobacco/about/index.html); [CDC Economic Trends in Tobacco (2024)](https://www.cdc.gov/tobacco/php/data-statistics/economic-trends/index.html)

<a id="heading-1.1.2"></a>

#### 1.1.2 Cytisinicline Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

ORCA-2 randomized 810 participants and ORCA-3 randomized 792 participants. With 12 weeks of cytisinicline, continuous abstinence during weeks 9–12 was 32.6% versus 7.0% with placebo in ORCA-2 and 30.3% versus 9.4% in ORCA-3. During weeks 9–24, the corresponding rates were 21.1% versus 4.8% and 20.5% versus 4.2%. Both trials provided behavioral support and reported no treatment-related serious adverse events.

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/); [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Cytisinicline

<a id="topic-1.1.3-1"></a>

##### Summary

ICER modeled a five-year U.S. budget impact using a hypothetical $5,000 price for a 12-week course. At that price, 4.3% of the eligible population could be treated without exceeding its $880 million annual budget-impact threshold. The manufacturer had not announced a U.S. price.

Source: [ICER final evidence report (2026)](https://icer.org/wp-content/uploads/2026/02/ICER_Smoking-Cessation_Final-Report_For-Publication_021226.pdf); [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-medication-for-smoking-cessation/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Two placebo-controlled phase 3 trials demonstrated higher smoking-abstinence rates with cytisinicline plus behavioral support than with placebo plus behavioral support. The sponsor reported an FDA complete response letter citing manufacturing deficiencies and unfinished product labeling, without efficacy or clinical safety deficiencies, and anticipated potential approval in the first half of 2027. This remains an anticipated regulatory outcome, not an approval. Economic findings depend on an unannounced U.S. price.

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/); [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/); [Achieve Life Sciences complete response letter announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/264/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda); [Achieve Life Sciences second quarter 2026 results announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/268/achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-updates); [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-medication-for-smoking-cessation/)

## Related pages
- [Cytisinicline in Smoking cessation: Terms and abbreviations](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations.md)
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary.md)
- [Cytisinicline in Smoking cessation: Product information and disease description](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description.md)
- [Cytisinicline in Smoking cessation: Clinical evidence](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence.md)
- [Cytisinicline in Smoking cessation: Economic information and modeling report](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics.md)
- [Cytisinicline in Smoking cessation: References](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references.md)
- [Cytisinicline in Smoking cessation: prevalence by geography](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence.md)
- [Cytisinicline in Smoking cessation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses.md)
